Compare Abbott Laboratories (ABT) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs HCA Health Inc — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while HCA Health Inc trades at $411.56 (market cap $93.86B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | HCA | |
|---|---|---|
Market Cap | $166.94B | $93.86B |
Sector | Health | Health |
52-Week High | $136.62 | $545.13 |
52-Week Low | $82.57 | $334.32 |
Enterprise Value | $193.69B | $142.77B |
Dividend Yield | 2.63% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
HCA Healthcare trades at $423.11, up 3.07% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats. Recent news highlights capacity expansion and gene therapy advancements. Technical indicators suggest bullish trends, though RSI signals potential overbought conditions near-term.
Outlook remains positive given earnings momentum and strategic investments, but risks include high debt levels and healthcare regulatory pressures. Analyst consensus targets $493 with 65% buy ratings, indicating upside potential from current levels amid manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
